Genmab fundamentals

Use Genmab A-S fundamentals concurrently with your other holdings, portfolios, and investing themes to protect against small markets fluctuations and to back test it against optimization strategy that fits your risk preferences.  Analyze Themes

Genmab competes with CITIGROUP, AP MOELLER, AP MOELLER, AKBANK, and INPEX. Its solutions in development include Ofatumumab, a human monoclonal antibody for the treatment of chronic lymphocytic leukemia, nonHodgkin?s lymphoma, diffuse large Bcell lymphoma, Waldenstrom?s macroglobulinemia, rheumatoid arthritis, and relapsing remitting multiple sclerosis; Zalutumumab, a human antibody that targets the epidermal growth factor receptor; and Daratumumab, a human antibody to target the CD38 molecule expressed on the surface of multiple myeloma tumor cells. Genmab A/S?s other clinical programs comprise RG4930 that is in phase II development for asthma targeting OX40L; and RG1512 targeting Pselectin, which is in phase II study for treatment of cardiovascular diseases. Its preclinical solutions include HuMaxTF ADC, HuMaxcMet, HuMaxTF ADC, HuMaxHer2, and HuMaxCD74 ADC for the treatment of cancer. Genmab A/S has collaboration agreements with GlaxoSmithKline to codevelop and commercialize ofatumumab; Roche to conduct clinical studies with RG4930 and RG1512 antibodies; H. Lundbeck A/S to create and develop human antibody therapeutics for disorders of the central nervous system; and Seattle Genetics, Inc. for the development of HuMaxTF, an antibodydrug conjugate. Genmab A/S was founded in 1999 and is based in Copenhagen, Denmark.